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Background: The myogenic response is an inherent vasoconstrictive property of resistance 32 
arteries to keep blood flow constant in response to increases in intravascular pressure. 33 
Angiotensin II (Ang II) type 1 receptors (AT1R) are broadly distributed, mechanoactivated 34 
receptors, which have been proposed to transduce myogenic vasoconstriction. However, the 35 
AT1R subtype(s) involved and their downstream G protein- and β-arrestin-mediated signaling 36 
pathways are still elusive. Objective: To characterize the function of AT1aR and AT1bR in 37 
the regulation of the myogenic response of resistance size arteries and possible downstream 38 
signaling cascades mediated by Gq/11 and/or β-arrestins. Methods: We used Agtr1a
-/-, 39 
Agtr1b-/- and tamoxifen-inducible smooth muscle-specific AT1aR knockout mice (SM-Agtr1a 40 
mice). FR900359, [Sar1, Ile4, Ile8] Ang II (SII) and TRV120055 were used as selective Gq/11 41 
protein inhibitor and biased agonists to activate non-canonical β-arrestin and canonical Gq/11 42 
signaling of the AT1R, respectively. Results: Myogenic and Ang II-induced vasoconstrictions 43 
were diminished in the perfused renal vasculature of Agtr1a-/- and SM-Agtr1a mice. Similar 44 
results were observed in isolated pressurized mesenteric and cerebral arteries. Myogenic 45 
tone and Ang II- induced vasoconstrictions were normal in arteries from Agtr1b-/- mice. The 46 
Gq/11 blocker FR900359 decreased myogenic tone and Ang II vasoconstrictions while 47 
selective biased targeting of AT1R β-arrestin signaling pathways had no effects. Conclusion: 48 
The present study demonstrates that myogenic arterial constriction requires Gq/11-dependent 49 
signaling pathways of mechanoactivated AT1aR but not G protein-independent, noncanonical 50 
alternative signaling pathways in the murine mesenteric, cerebral and renal circulation. 51 
1. Introduction 52 
Myogenic vasoconstriction reflects the inherent ability of resistance arteries to adapt their 53 
diameter in response to alterations of intraluminal pressure. This response was first described 54 
by William Bayliss (2) and it reflects changes to the contractile state of vascular smooth 55 
muscle.   Increases in transmural pressure cause vasoconstriction whereas decreases 56 
produce the opposing effect; this prototype of autoregulation has been observed in various 57 
microvascular arterial beds (8) and it is responsible for maintaining constant blood flow during 58 
fluctuations in perfusion pressure. Many cardiovascular disorders are associated with 59 
dysfunctional arterial myogenic response and they include hypertension, chronic heart failure, 60 
ischemic stroke, diabetes mellitus (6) (14) (31) (41) (45). Despite the functional importance of 61 
the myogenic response, the molecular mechanisms responsible for sensing intraluminal 62 
pressure has yet to be fully clarified.   63 
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 Myogenic vasoconstriction is mediated by pressure-dependent depolarization of vascular 64 
smooth muscle cells, an event that augments Ca2+ influx through voltage-dependent Cav1.2 65 
channels (39) (7) (9) (16) (17) (38). Gq/11-coupled receptors (GPCRs) are thought to function 66 
as the upstream sensor of membrane stretch (37), with angiotensin II type 1a (AT1aR), and 67 
perhaps AT1bR receptors in concert with cysteinyl leukotriene 1 receptor (CysLT1R), playing 68 
a particularly important role in the mesenteric and renal circulation (3) (40) (46) (49). AT1Rs 69 
are known to couple primarily to classical Gq/11 proteins to activate multiple downstream 70 
signals, including protein kinase (PKC), extracellular signal-regulated kinases (ERK1/2), Raf 71 
kinases, tyrosine kinases, receptor tyrosine kinases (EGFR, PDGF, insulin receptor) and 72 
reactive oxygen species (ROS) (1). The AT1R activation also stimulates G 73 
protein-independent signaling pathways such as β-arrestin-mediated mitogen-activated 74 
protein kinase (MAPK) activation and Src-JAK/STAT (1). Recently, it has been shown that the 75 
activation of intracellular signaling by mechanical stretch of the AT1R does not require the 76 
natural ligand angiotensin II (Ang II) (44) (55) (46) but requires the activation of the transducer 77 
ß-arrestin (44). Interestingly, mechanical stretch appears to allosterically stabilize specific 78 
β-arrestin-biased active conformations of AT1R to promote noncanonical downstream 79 
signaling mediated exclusively by the multifunctional scaffold protein, β-arrestin (50).  80 
Whether this noncanonical ß-arrestin effector pathway plays a role in myogenic and 81 
ligand-dependent vasoconstriction has yet to be ascertained. 82 
 This study explored the specific function of AT1R subtypes in the regulation of myogenic 83 
tone and whether downstream signaling pathways are dependent on canonical Gq/11 and/or 84 
noncanonical alternative signaling pathways. In this regard, we generated mice with cell 85 
specific deletion of smooth muscle AT1a receptors (SM-Agtr1a mice) and studied the effects 86 
of biased GPCR agonists and Gq/11 protein inhibition on tone development in three distinct 87 
vascular beds (renal, cerebral and mesenteric circulation). We found that the AT1aR coupled 88 
towards the canonical Gq/11 signaling pathway is required for the myogenic response in all 89 
three vascular beds. Our data argue against involvement of noncanonical G 90 
protein-independent alternative signaling downstream of the AT1aR to cause myogenic 91 
vasoconstriction. 92 
2. Materials and Methods 93 
2.1 Mouse Model 94 
We used the SMMHC-Cre-ERT2 transgenic mouse line expressing Cre recombinase in 95 
smooth muscle cells under control of the smooth muscle myosin heavy chain promoter (26) 96 
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and a mouse line bearing a floxed allele of the Agtr1a gene (Agtr1aflox), encoding the major 97 
murine AT1 receptor isoform (AT1aR) (48) to generate SMMHC-Cre+Agtr1aflox/flox 98 
(SM-Agtr1a-/-) mice (Figure 1A). Genotyping was performed by polymerase chain reaction 99 
(PCR) analysis of tail DNA as described previously (26). Amplification of the SMMHC-Cre 100 
gene was performed in a multiplex PCR with the primers TGA CCC CAT CTC TTC ACT CC 101 
(SMWT1), AAC TCC ACG ACC ACC TCA TC (SMWT2), and AGT CCC TCA CAT CCT CAG 102 
GTT (phCREAS1) (13). The following primers (5’-3’) were used to identify Agtr1aflox alleles: 103 
forward GCT TTC TCT GTT ATG CAG TCT, reverse ATC AGC ACA TCC AGG AAT G. Adult 104 
(12-16 weeks) male mice were injected with tamoxifen (30 µg/mg body weight) on 5 105 
consecutive days. Isolated arteries were usually obtained after 2 to 3 days after tamoxifen 106 
treatment. Figure 1B shows reduction of AT1aR expression in vascular smooth muscle cells 107 
of SM-Agtr1a-/- arteries. We also studied adult (12-16 weeks) male mice with global AT1a 108 
receptor deficiency (Agtr1a-/-) (24) (46) (25), and with global AT1b receptor deficiency 109 
(Agtr1b-/-) (40). Age-matched male mice were used as controls in the experiments. Animal 110 
care followed American Physiological Society guidelines, and all protocols were approved by 111 
local authority (LAGeSo, Berlin, Germany) and the animal welfare officers of the Max 112 
Delbruck Center for Molecular Medicine. Mice were maintained in the Max Delbrück Center 113 
animal facility in individually ventilated cages (Tecniplast, Deutschland) under standardized 114 
conditions with an artificial 12-hour dark-light cycle, with free access to standard chow (0.25% 115 
sodium; SSNIFF Spezialitäten, Soest, Germany) and drinking water. Animals were randomly 116 
assigned to the experimental procedures. 117 
2.2 Materials 118 
Antibody to α-smooth muscle actin (α-SMA, #ab8211) was from Abcam (Cambridge, MA, 119 
USA). Anti-AT1R (#PA5-20812) and donkey anti-rabbit IgG (H+L) secondary antibody 120 
(A10040) were purchased from Thermo Fisher Scientific (Waltham, MA, USA). 121 
4',6-diamidino-2-phenylindole (DAPI, #D9542) was purchased from Sigma-Aldrich Co. (St. 122 
Louis, MO, USA). Ang II (#A9525), SII (#sc-391239A) and tamoxifen (#H7904) were from 123 
Sigma-Aldrich Co (82024 Taufkirchen, Germany). TRV120055 (#JT-71995) and TRV120056 124 
(#JT-71996) were from Synpeptide Co., Ltd (Shanghai, China). 125 
2.3 Mesenteric and cerebral arteries 126 
After mice were killed, the mesenteric bed and brain were removed and placed into cold (4°C), 127 
gassed (95% O2-5% CO2) physiological saline solution (PSS) of the following composition 128 
(mmol/L): 119 NaCl, 4.7 KCl, 25 NaHCO3, 1.2 KH2PO4, 1.6 CaCl2, 1.2 MgSO4, 0.03 EDTA, 129 
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and 11.1 glucose. Third or fourth order mesenteric and middle cerebral arteries or posterior 130 
cerebral arteries were dissected and cleaned of adventitial connective tissue (46) (18) (10) 131 
(11). 132 
2.4 Pressure myography 133 
Vessel myography was performed as previously described (26) (37) (46) (10). Mesenteric or 134 
cerebral arteries were mounted on glass cannula and superfused continuously with PSS (95% 135 
O2-5% CO2; pH, 7.4; 37°C). The vessels were stepwise pressurized to 20, 40, 60, 80, or 100 136 
mmHg using a pressure servo control system (Living System Instrumentation, Burlington, VT). 137 
We measured the inner diameter of the vessels with a video microscope (Nikon Diaphot, 138 
Düsseldorf, Germany) connected to a personal computer for data acquisition and analysis 139 
(HaSoTec, Rostock, Germany) (18) (19) (46) (11) (10). Arteries were equilibrated for 45 to 60 140 
minutes before starting experiments. A 60-mmol/L KCl challenge was performed before any 141 
other intervention. 142 
2.5 Analysis of myogenic tone in isolated perfused kidneys 143 
Isolated kidneys were perfused in an organ chamber using a peristaltic pump at constant flow 144 
(0.3-1.9 ml/min) of oxygenated (95% O2 and 5% CO2) PSS (46). Drugs (Ang II or biased 145 
agonists) were added to the perfusate. Perfusion pressure was measured by a pressure 146 
transducer after an equilibration period of 60-90 min. Data were recorded and analyzed by a 147 
Powerlab acquisition system (AD Instruments, Colorado Springs). Ang II-induced pressor 148 
effects were normalized to the maximal pressor effect induced by KCl (60 mmol/L) (37) (46) 149 
(18). 150 
2.6 Immunofluorescence 151 
Agtr1a+/+ and SM-Agtr1a-/- mice mesenteric arteries were dissected and further fixed in 4% 152 
formaldehyde and embedded in Tissue-Tek O.C.T. compound to be frozen in liquid nitrogen. 153 
Tissues were then sectioned and permeabilized in 1% Triton X-100 in PBS. Sections were 154 
stained with the primary antibody overnight at 4°C. After washing with PBS for 3×5 min, the 155 
secondary antibody and DAPI were applied for 2 hours at room temperature. Fluorescence 156 
images were captured by use of Olympus FV1000 confocal microscopy and images were 157 
analyzed by ImageJ analysis software.  158 
2.7 Statistics 159 
Data are presented as means ± SEM. Statistically significant differences in mean values were 160 
determined by Student's unpaired t test or one-way analysis of variance (ANOVA). P values < 161 
0.05 were considered statistically significant. 162 
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3. Results 164 
3.1 AT1aR is essential for pressure-induced response in the renal circulation 165 
We evaluated myogenic tone in mouse renal circulation, a highly myogenic bed regulating 166 
blood flow to the kidneys and consequently sodium excretion and systemic blood pressure. 167 
Renal vascular resistance of isolated perfused kidneys was determined by measuring 168 
perfusion pressure at fixed levels of flow. The perfusion pressure increased with flow rate in 169 
kidneys of wild-type Agtr1a+/+ mice, reaching a value of about 160 mmHg at a flow rate of 1.9 170 
ml/min (Figure 2A). Kidneys from Agtr1a-/- mice developed significantly less pressure at the 171 
same flow rate (Figure 2B, E). 60 mmol/L KCl-induced increases in perfusion pressure were 172 
normal in Agtr1a-/- kidneys (Figure 2 F). At a flow rate of 1.9 ml/min, pressure in Agtr1a-/- 173 
kidneys was ~100 mmHg lower than in Agtr1a+/+ kidneys. Angiotensin II (Ang II, 10 nmol/L) 174 
increased perfusion pressure by ~80 mmHg in kidneys of Agtr1a+/+ mice, but had no effect in 175 
kidneys of Agtr1a-/- mice (Figure 2C); this is indicative of AT1aRs mediating Ang II-dependent 176 
vasoconstriction. Removal of external Ca2+ nearly abolished flow-induced myogenic 177 
constriction in perfused kidneys of Agtr1a+/+ mice, but had nearly no effect in kidneys of 178 
Agtr1a-/- mice (Figure 2D), indicating AT1aRs mediate also myogenic constriction of mouse 179 
renal arterioles. Of note, there was no difference in myogenic tone and Ang II 180 
vasoconstrictions between Agtr1b-/- versus Agtr1b+/+ kidneys (Figure 3).   181 
Next we focused on kidneys from SM-Agtr1a-/- mice (Figure 4). At a flow rate of 1.9 ml/min, 182 
pressure in SM-Agtr1a-/- kidneys was ~90 mmHg lower than in Agtr1a+/+ kidneys (Figure 4 A, 183 
B, E). SM-Agtr1a-/- kidneys showed largely reduced myogenic vasoconstriction as assessed 184 
by exposure of the kidneys to Ca2+ free PSS (Figure 4B, D), whereas wild-type kidneys 185 
showed strong myogenic vasoconstrictions (Figure 4A, D). 60 mmol/L KCl-induced increases 186 
in perfusion pressure were normal in Agtr1a-/- kidneys (Figure 4F). Ang II (10 nmol/L) induced 187 
weaker increases in perfusion pressure in kidneys of SM-Agtr1a-/- mice compared to controls 188 
(Figure 4D). Together, these results reveal a key role of AT1aR but not AT1bR in the 189 
flow-induced myogenic response of the mouse renal vasculature. 190 
3.2 AT1aR contribute to myogenic constriction in mesenteric arteries 191 
We monitored myogenic constriction in resistance-sized mesenteric arteries using 192 
videomicroscopy. Mesenteric arteries were exposed to stepwise (20 mmHg) increases in 193 
intraluminal pressure (20-100 mmHg) in the presence and absence of external Ca2+ (1.6 194 
mmol/L) to determine active and passive vessel diameters, respectively. Figure 5 shows 195 
.CC-BY 4.0 International licensepreprint (which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for thisthis version posted September 11, 2020. . https://doi.org/10.1101/2020.09.09.289280doi: bioRxiv preprint 
7 
 
representative recordings of mesenteric arteries from Agtr1a+/+ mice (Figure 5A) and 196 
SM-Agtr1a-/- mice (Figure 5B) and myogenic vasoconstriction was defined as the diameter 197 
difference in the presence and absence of external Ca2+ (1.6 mmol/L) at each pressure step 198 
(46). Increases in intraluminal pressure generated active tension that counteracted further 199 
dilation of the vessels at 60 to 80 mmHg in mesenteric arteries from Agtr1a+/+ mice, reaching 200 
peak constrictions of 50 μm at 80 to 100 mmHg (Figure 5A). In contrast, mesenteric arteries 201 
from SM-Agtr1a-/- mice only produced ~35% of the constriction observed in wild-type arteries 202 
(Figure 5B, C). Ang II strongly constricted arteries from Agtr1a+/+ mice but had no effect on 203 
arteries from SM-Agtr1a-/- mice (Figure 5D); the latter did constrict in response to 60 mmol/L 204 
KCl (Figure 5E). This study observed a marked reduction in AT1aR expression in the media 205 
of SM-Agtr1a-/- mesenteric arteries compared to wild-type (Figure 1B), in keeping with this 206 
receptor mediating myogenic constriction in mesenteric arteries.   207 
3.3 AT1aR contribute to myogenic constriction in cerebral arteries 208 
Next, we studied the function of AT1aRs in cerebral arteries. Vessels were equilibrated at 15 209 
mmHg (30 min) and following an assessment of KCl-induced constriction, arteries were 210 
pressurized to 80 mmHg (Figure 6A). Ang II constrictions and myogenic constriction was 211 
significantly decreased in SM-Agtr1a-/- arteries compared to wild-type (Figure 6A, B, C, D). 212 
Both wild-type and SM-Agtr1a-/- arteries produced similar constrictions when exposed to 60 213 
mmol/L KCl (Figure 6E). The results demonstrate a key role of AT1aR in the myogenic 214 
response of mouse cerebral arteries. 215 
3.4 Gq/11 protein dependent signaling pathway is responsible for myogenic tone 216 
To explore the role of Gq/11 and β-arrestin signaling pathways downstream of AT1R, we used 217 
the biased agonists TRV120055 and SII to activate Gq/11 and β-arrestin signaling pathways, 218 
respectively (29) (34) (51). We found that TRV120055 increased vascular tone in mesenteric 219 
arteries (Figure 7A, B), whereas SII had no effect (Figure 7C, D). Similarly, TRV120055 and 220 
TRV120056 (another biased Gq/11 coupled AT1R agonist) enhanced dose-dependent 221 
perfusion pressure in isolated kidneys (Figure 8A, C), whereas SII had no effect (Figure 8B, 222 
C). The removal of external Ca2+ abolished agonist-induced vasoconstrictions in perfused 223 
kidneys (Figure 8D), indicating AT1aRs mediate vasoconstriction via canonical Gq/11 but not 224 
noncanonical β-arrestin pathways. To confirm the results, we next examined the effects of 225 
FR900359, a selective Gq/11-protein inhibitor (23) (47) (35). FR900359 abolished both 226 
myogenic and Ang II-dependent constrictions in renal arterioles (Figure 9) and mesenteric 227 
arteries (Figure 7E, F). These results indicate that myogenic vasoconstriction is mediated 228 
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through the mechanosensitive AT1aR and the canonical Gq/11 signaling pathway.  229 
4. Discussion 230 
The study found that the canonical Gq/11 signaling of mechanoactivated AT1aR is responsible 231 
for myogenic vasoconstriction in mesenteric, renal arteries and cerebral arteries. We 232 
observed a loss of myogenic autoregulation in the renal circulation of Agtr1a-/- mice, an effect 233 
which was normal in Agtr1b-/- mice. Similarly, we found that myogenic tone was strongly 234 
reduced in two other myogenic arteries (mesentery and cerebral) from smooth muscle 235 
specific AT1aR-deficient (SM-Agtr1a-/-) mice compared to wild-type. Using the 236 
pharmacological Gq/11 inhibitor FR900359 and several GPCR biased agonists, we showed 237 
that AT1Rs cause vasoconstriction via canonical Gq/11 signaling but not alternative G protein 238 
signaling downstream of the AT1R. 239 
AT1aRs are primary mechanosensors in intact arteries 240 
Multiple GPCRs have been proposed to act as mechanosensors to regulate myogenic tone in 241 
resistance arteries. While stretch induces activation of purinergic P2Y6 UDP receptors, 242 
thromboxane A2 (TP) receptors and sphingosine-1-phosphate (S1P) receptors in certain 243 
vascular beds (27) (28) (30), the AT1R remains one of the best characterized mechanosensor 244 
in the vasculature (49) (55). Humans express a single type of AT1R, whereas two isoforms 245 
(AT1aR and AT1bR) are present in rodents (36) (53). Using Agtr1a-/- mice and inverse AT1R 246 
agonist, our previous data suggested that ligand-independent AT1aR activation is required for 247 
myogenic response in resistance mesenteric arteries and renal arterioles (46). However, two 248 
recent studies reported that myogenic tone was diminished in Agtr1b-/- mesenteric and 249 
cerebral arteries, which implies a possible role of AT1bRs in mechanosensation (42) (3). In 250 
contrast, we found that myogenic tone was normal in Agtr1b-/- perfused kidneys, which argues 251 
against a role of AT1bR in myogenic constriction in the renal circulation.  This data was, 252 
however, obtained in global mutant mice, which often display compensatory mechanisms for 253 
the lack of AT1Rs. Moreover, AT1aR and AT1bR are expressed at similar levels in cerebral 254 
parenchymal arterioles and genetic knockout of AT1aR (but not AT1bR) blunted the ability of 255 
these vessels to generate myogenic tone (52). The latter effect is opposite to cerebral arteries 256 
where genetic knockout of AT1bR blunted the ability to develop myogenic tone (42). To 257 
overcome these potential limitations, we generated tamoxifen-inducible SM-Agtr1a 258 
(SMMHC-Cre+Agtr1aflox/flox) mice for careful phenotypic investigation. We found that myogenic 259 
constriction was impaired in cerebral, mesenteric and renal arteries isolated from smooth 260 
muscle AT1aR-deficient mice. The data provide firm evidence that AT1aRs play a key role as 261 
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mechanosensors mediating myogenic constriction in the murine vasculature. 262 
AT1aRs downstream signaling to cause vasoconstriction 263 
We next explored downstream signaling pathways mediated by Gq/11 and/or β arrestins of the 264 
AT1R in the vascular response. In cell culture, osmotic cell stretch has been found to increase 265 
the binding affinity and potency of the β-arrestin-biased agonist TRV120023 with no effect on 266 
the balanced agonist Ang II through AT1R to induce a conformation change of β-arrestin 2, 267 
similar to that induced by β-arrestin-biased agonists (50). Similarly, hypo-osmotic stretch 268 
induced β-arrestin-biased signaling of AT1Rs in the absence of G protein activation (44). We 269 
failed to observe β-arrestin mediated enhancement of myogenic vasoconstriction with the 270 
β-arrestin biased agonist SII in intact arteries (mesenteric and renal arteries: Figure 10). The 271 
discrepancy might be caused by differences between the hypo-osmotic cell swelling and 272 
tensile stretch on the smooth muscle cell layer in intact arteries to cause mechanoactivation of 273 
AT1aRs in situ. GPCRs biased mechanisms have been described between two different G 274 
proteins, between β-arrestin-1 and 2, and between different states of the same receptor 275 
bound to different ligands (12) (21) (54). However, the majority of well described GPCRs 276 
biased ligand examples refers to selective G protein signaling versus β-arrestin-mediated 277 
signaling (20) (33) (43) (51). AT1aR is one of the best characterized GPCR enabling biased 278 
receptor signaling. It can be activated in either a canonical G protein-dependent signaling 279 
mode (5) (37) or noncanonical β-arrestin-mediated signaling mode (44) (50). In line, we found 280 
that the natural biased agonist Ang II was able to increase G protein signaling of 281 
mechanoactivated AT1R receptors to enhance the vasoconstrictor response.    282 
 We hypothesized that Gq/11 signaling contributes to myogenic tone in mesenteric and 283 
renal arteries and consistent with this idea, we found that the vasoconstrictor responses were 284 
strongly increased by the Gq/11 AT1R biased agonists TRV120055 and TRV20056 (Figure 10).  285 
Moreover, we found that the Gq/11 blocker FR900359 inhibited both myogenic tone and Ang II 286 
induced constrictions in mesenteric arteries and renal arterioles (Figure 10). The data imply 287 
that myogenic vasoconstriction requires canonical Gq/11 signaling of the AT1aR. Consistently, 288 
myogenic tone is increased in the absence of regulator of G-protein signaling 2 (RGS2), 289 
which is an endogenous terminator of Galphaq/11 (Gαq/11) signaling (19) (37). The data align 290 
with findings indicating that mechanically activated AT1R generate diacylglycerol, which in 291 
turn activates protein kinase C (PKC) and induces the actin cytoskeleton reorganization 292 
necessary for pressure-induced vasoconstriction (22). Finally, our conclusions are supported 293 
by findings indicating that another Gq/11-protein inhibitor YM 254890 profoundly reduced 294 
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myogenic tone in mesenteric arteries (49). Note, this data contrast with recent findings, which 295 
proposed that G12/13- and Rho/Rho kinase-mediated signaling is required in myogenic 296 
vasoconstriction by inhibition of myosin phosphatase (5). The reason for the discrepancy is 297 
presently unknown, but may depend on which vessel order was utilized, i.e. 3rd or 4th order 298 
mesenteric versus 1st or 2nd order mesenteric arteries. Moreover, the myogenic response was 299 
only reduced by 50% in G12/13-deficient cerebral arteries (5), which may indicate that this 300 
pathway may play a role in some but not all vessels. Thus, it is possible that the relevance to 301 
the two signaling pathway differs between various vascular beds and artery branches. Our 302 
study provides firm evidence that AT1aRs coupled to Gq/11 signaling is an essential 303 
component of dynamic mechanochemical signaling in arterial vascular smooth muscle cells 304 
causing myogenic tone (Figure 10).  305 
 Signaling of most GPCRs via G proteins is terminated (desensitization) by the 306 
phosphorylation of active receptor by specific kinases (GPCR kinases, or GRKs) and 307 
subsequent binding of ß-arrestins that selectively recognize active phosphorylated receptors. 308 
Although, GRKs and ß-arrestins play also a role in multiple noncanonical signaling pathways 309 
in the cell, both GPCR-initiated and receptor-independent (32) (15), our study failed to 310 
demonstrate that this pathway plays an important role in the myogenic response (Figure 10). 311 
Thus, it is unlikely that blood pressure lowering effects of ß-arrestin biased AT1R agonists, 312 
e.g. Trevena 120027 (4), are caused by direct effects of this GPCR in the arterial smooth 313 
muscle cells.  314 
 In summary, we provide new and firm evidence for a mechanosensitive function of 315 
AT1aR in myogenic vasoconstriction in mesenteric, renal and cerebral arteries, i.e. in three 316 
different highly myogenic vascular beds. Our study clearly shows that mechanical stress 317 
activates AT1R in arterial smooth muscle cells, which subsequently triggers canonical Gq/11 318 
signaling, irrespective of GRK/β-arrestin signaling, to cause myogenic vasoconstriction. Our 319 
results argue against the idea of multiple mechanosensors coupled to noncanonical β-arrestin 320 
pathways generating myogenic arterial tone. These findings lay ground for additional studies 321 
to characterize the molecular mechanisms of mechanoactivated AT1aR coupled to Gq/11 322 
signaling in intact arteries, which may reveal new molecular targets for drug development to 323 
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Figure legends 521 
Figure 1: Conditional deletion of AT1a receptors in vascular smooth muscle cells of 522 
arteries. A: Schematic representation of the mouse allele containing loxP sequences, and the 523 
floxed allele after the action of Cre recombinase. B: Immunofluorescence staining results 524 
show that AT1R (red) is highly expressed in the mesenteric artery of Agtr1a+/+ mice. In 525 
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SM-Agtr1a-/- mouse mesenteric artery, the expression of AT1R is specifically reduced in 526 
smooth muscle cells. Scale bar: 40 μm. 527 
Figure 2: Vasoregulation in isolated perfused kidneys of Agtr1a-/- mice.  A, B: Original 528 
recordings of perfusion pressure in kidneys of Agtr1a+/+ (A) and Agtr1a-/- mice (B). C: Increase 529 
in the perfusion pressure induced by 100 nM Ang II. D: Myogenic tone assessed by exposure 530 
to Ca2+ free PSS. E: Perfusion pressure at flow rates of 0.3 ml/min, 0.7 ml/min, 1.3 ml/min and 531 
1.9 ml/min. F: Increase in the perfusion pressure induced by 60mM KCl. n=6 Agtr1a+/+ kidneys 532 
and n=7 Agtr1a-/- kidneys for all panels. *p<0.05; n.s., not significant. 533 
Figure 3: Vasoregulation in isolated perfused kidneys of Agtr1b-/- mice.  A, B: Original 534 
recordings of the perfusion pressure in kidneys of Agtr1b+/+ (A) and Agtr1b-/- mice (B). C: 535 
Increase in perfusion pressure induced by 10 nM Ang II. D: Change of pressure assessed by 536 
exposure to Ca2+ free PSS. E: Perfusion pressure at flow rates of 0.3 ml/min, 0.7 ml/min, 1.3 537 
ml/min and 1.9 ml/min. F: Increase in perfusion pressure induced by 60 mM KCl. n=6 538 
Agtr1b+/+ kidneys and n=6 Agtr1b-/- kidneys for all panels. w.o., wash-out; n.s., not significant. 539 
Figure 4: Vasoregulation in isolated perfused kidneys of SM-Agtr1a-/- mice.  A, B: 540 
Original recordings of the perfusion pressure in kidneys of Agtr1a+/+ (A) and SM-Agtr1a-/- mice 541 
(B). C: Increase in perfusion pressure induced by 10 nM Ang II. D: Change of pressure 542 
assessed by exposure to Ca2+ free PSS. E: Perfusion pressure at flow rates of 0.3 ml/min, 0.7 543 
ml/min, 1.3 ml/min, and 1.9 ml/min. F: Increase in perfusion pressure induced by 60 mM KCl. 544 
n=6 Agtr1a+/+ kidneys and n=6 SM-Agtr1a-/- kidneys for all panels. *p<0.05; n.s., not 545 
significant. 546 
Figure 5: Myogenic tone in mesenteric arteries. A, B: Representative recordings of MA 547 
diameter during a series of pressure steps from 20 to 100 mmHg in 20 mmHg increments in 548 
control conditions (+Ca2+) and in Ca2+ free solution (-Ca2+). Arteries were isolated from 549 
Agtr1a+/+ (A) and SM-Agtr1a-/- mice (B). Note the increase in active constriction over the entire 550 
pressure range from 60 to 100 mmHg in vessels from Agtr1a+/+, but not from SM-Agtr1a-/- 551 
mice. Vasodilation in Ca2+-free solution was observed in Agtr1a+/+ but not in SM-Agtr1a-/- 552 
arteries (P<0.05). C: Myogenic tone (at 80 mmHg) expressed as dilation of vessels induced 553 
by external Ca2+ free solution (0 Ca/EGTA; n=6). D to G: Response to angiotensin II (Ang II; 554 
D, E) and 60 mM KCl (F, G) in MA of Agtr1a+/+ and SM-Agtr1a-/- mice. MAs were pressurized 555 
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to 60 mmHg. Responses are expressed as relative changes in vessel inner diameter. 556 
Agtr1a+/+, n=5 vessels and SM-Agtr1a-/-, n=4 vessels for each group. *p<0.05. 557 
Figure 6: Myogenic tone in cerebral arteries. A, B: Representative recordings of 558 
middle/posterior cerebral arteries diameter at the pressure of 80 mmHg in control conditions 559 
(WT), Ang II 100 nmol/L, and in Ca2+ free solution. C: Myogenic tone (at 80 mmHg) expressed 560 
as dilation of vessels induced by external Ca2+ free solution. D, E: Response to Ang II (D) and 561 
60 mM KCl (E) in middle/posterior cerebral arteries of Agtr1a+/+ and SM-Agtr1a-/- mice. 562 
Agtr1a+/+, n=6 vessels and SM-Agtr1a-/-, n=6 vessels for each group. * p<0.05. 563 
Figure 7: Enhancement of the vascular tone by TRV120055. A, C, and E Representative 564 
recordings of mesenteric artery diameter during a series of pressure steps from 20 to 100 565 
mmHg in 20 mmHg increments in control conditions (+Ca2+), TRV120055 100 nmol/L (A), SII 566 
100 nmol/L (C), FR120055 1 µmol/L (E) and in Ca2+-free solution. B, D and F: Average 567 
myogenic constriction of mesenteric arteries in drug-free physiological salt solution (PSS) and 568 
in PSS containing 100 nmol/L TRV120055 (B), 100 nmol/L SII (D), and 1 µmol/L FR120055 569 
(F) (n=6, 4 and 4, respectively). G and H: Response to Ang II in MA in drug-free PSS and 570 
PSS in presence of FR120055 at 80 mmHg (n=6 each). *p<0.05; n.s., not significant. 571 
Figure 8: Function of biased AT1R agonists to vasoregulation in isolated perfused 572 
kidneys from Agtr1a+/+ mice.  A, B: Original recordings of perfusion pressure in response 573 
to various flow rates (in ml/min), TRV120055 (A) or Sar-Ile II (B), Ca2+ free perfusion solution 574 
(PSS Ca2+ free) and re-exposure of the kidneys to PSS. C: Increase in perfusion pressure 575 
induced by TRV120055 and Sar-Ile II in various concentrations (10 nM to1 µM). D: Change of 576 
perfusion pressure assessed by exposure of the kidneys to Ca2+ free PSS at the presence of 577 
TRV120055 or Sar-Ile II at the concentration of 100 nM. E: Dose-response relationships for 578 
TRV120055 and TRV120056. F: Increase in perfusion pressure induced by 60 mM KCl. 579 
TRV120055, TRV120056, Sar-Ile II. n=6 kidneys in each group; n=6 kidneys in the control 580 
group. *p<0.05; n.s., not significant; Control, Agtr+/+ without biased ligand. 581 
Figure 9: Vasoregulation in isolated perfused kidneys of Agtr1a+/+ mice pretreated with 582 
300 nM Gq/11 blocker FR900359. A: Original recordings of perfusion pressure in kidneys of 583 
Agtr+/+ mice in response to various concentrations of Angiotensin II (Ang II) B: same as A but 584 
pretreated with 300 nM FR900359 for 30 minutes. C: Increases in perfusion pressure induced 585 
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by Ang II (1 nM to 1 µM). D: Myogenic tone assessed by exposure of the kidneys to Ca2+-free 586 
PSS. E: Increase in perfusion pressure induced by 60 mM KCl. n=5 Agtr+/+ kidneys and n=6  587 
Agtr1a+/+ kidneys pretreated with FR900359 for all panels. *p<0.05; w.o., wash-out; n.s., not 588 
significant. 589 
Figure 10: Schematic illustration of angiotensin II type 1a receptor (AT1aR) biased signaling 590 
cascade regulating myogenic arterial tone. Canonical Gq/11 signaling pathway of the AT1R 591 
(purple blue) causes myogenic vasoconstriction whereas noncanonical β-arrestin-biased 592 
signaling is not involved in this process. Gq/11 proteins are heterotrimeric G proteins, which are 593 
made up of alpha (α), beta (β) and gamma (γ) subunits. The alpha subunit is attached to 594 
either a guanosine triphosphate (GTP) or guanosine diphosphate (GDP), which serves as an 595 
on-off switch for the activation of the G-protein. Upon activation of the AT1aR by either 596 
ligand-independent mechanical stretch or the natural-biased ligand angiotensin II (Ang II), the 597 
Gβγ complex is released from the Gα subunit after its GDP-GTP exchange for canonical G 598 
protein signaling to cause myogenic and/or humoral (Ang II-mediated) vasoconstriction. This 599 
pathway is inhibited by the Gq/11 inhibitor FR900359. Although, GRKs and arrestins play a role 600 
in multiple noncanonical signaling pathways in cells, this pathway is unlikely engaged by 601 
mechanoactivated AT1Rs in response to tensile stretch or their natural ligand angiotensin II to 602 
cause vasoconstriction. 603 
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